Big Pharma Has Spent $8 Billion on Targeted Radiation. Alpha Tau Is Building for the Tumors They Can't Reach

TL;DR: Alpha Tau Medical Ltd. (NASDAQ: DRTS) is developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. Since late 2023, pharmaceutical giants have spent nearly $8 billion acquiring systemic radiopharmaceutical platforms that deliver radioactive payloads through the bloodstream. These work well for metastatic cancers but have limitations for localized solid tumors: the radiation needs a circulating target, and tumor penetration can be inconsistent. Alpha DaRT takes a complementary approach, delivering alpha radiation directly into tumors via implantable seeds. With a market cap around $615 million, recent data showing an 81% disease control rate in pancreatic cancer, and FDA Breakthrough Device Designations in three indications, Alpha Tau addresses a clinical gap that these systemic acquisitions don’t cover.

Since late 2023, pharmaceutical giants have deployed nearly $8 billion acquiring radiopharmaceutical platforms. Bristol Myers Squibb paid $4.1 billion for RayzeBio, adding an actinium-based alpha-particle platform. AstraZeneca acquired Fusion Pharmaceuticals for up to $2.4 billion in 2024. Eli Lilly paid $1.4 billion for Point Biopharma.

This surge follows earlier deals that established the category: Novartis’s $3.9 billion acquisition of Advanced Accelerator Applications in 2018 and Bayer’s $2.9 billion purchase of Algeta in 2014. The strategic logic is straightforward: radioligand therapies represent a growing market, projected to expand from approximately $3 billion in 2025 to nearly $11 billion by 2035.

What these platforms share is systemic administration, which excels at treating metastatic disease but has limitations for localized solid tumors that lack good circulating targets.

The Clinical Gap: Localized Solid Tumors

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) addresses a different clinical need. Rather than systemic delivery, Alpha DaRT uses small implantable sources containing radium-224 placed directly into tumors. As the radium decays, it releases short-range alpha particles that destroy cancer cells while limiting damage to surrounding tissue.

Bristol Myers paid $4.1 billion for RayzeBio specifically because alpha particles offer superior tumor-killing potency compared to beta emitters. Alpha Tau harnesses this same advantage, delivered locally rather than systemically.

This intratumoral delivery means Alpha DaRT can treat solid tumors that systemic therapies struggle to reach, including pancreatic, brain, and skin cancers. The FDA has granted Alpha Tau three Breakthrough Device Designations: for recurrent cutaneous squamous cell carcinoma, recurrent squamous cell carcinoma of the oral cavity, and recurrent glioblastoma. The company is also part of the FDA’s Total Product Life Cycle Advisory Program.

Clinical Progress Across Multiple Indications

Alpha Tau is conducting five FDA-approved clinical trials in the United States spanning skin, pancreatic, brain, and prostate cancers.

The most recent data came from the company’s first-in-human pancreatic cancer study. Results presented at the 2026 ASCO Gastrointestinal Cancers Symposium showed an 81% disease control rate across 32 patients with Stage II, III, or IV pancreatic ductal adenocarcinoma. Immune marker analysis demonstrated preservation of immune function, a characteristic not typical of conventional radiation therapy.

In December 2025, Alpha Tau treated the first patient in its U.S. glioblastoma trial at The Ohio State University, marking the first time Alpha DaRT has been used to treat brain cancer. The company also recently received FDA approval to initiate a trial for locally recurrent prostate cancer.

On the regulatory front, Alpha Tau submitted the first module of its Pre-Market Approval (PMA) application to the FDA in January 2026. The pivotal ReSTART trial for skin cancer is expected to complete enrollment in Q1 2026.

Commercial Preparation

Beyond clinical development, Alpha Tau is building manufacturing capacity. In October 2025, the company received a radioactive material license for its New Hampshire facility, a necessary step toward commercial-scale U.S. production.

In a January 2026 shareholder letter, CEO Uzi Sofer outlined expectations including completion of patient recruitment for both the ReSTART skin cancer trial and the IMPACT pancreatic cancer trial by end of Q1, with data readouts anticipated later in the year. The company also awaits a regulatory decision in Japan for recurrent head and neck cancer, which could represent its first commercial approval outside Israel.

With a market capitalization of approximately $615 million, Alpha Tau trades at a fraction of the valuations paid for other radiation oncology platforms. However, the company remains pre-revenue with ongoing clinical trials, and approval timelines carry inherent uncertainty.

Looking Ahead

Large pharma companies have clearly signaled that targeted radiation is a strategic priority, but those deals have focused on systemic platforms for metastatic disease, leaving a gap in localized solid tumors that Alpha Tau’s technology addresses.

The regulatory pathway, supported by Breakthrough Device Designations and an ongoing modular PMA submission, provides defined milestones. Whether large pharma eventually views localized alpha therapy as strategically valuable alongside their systemic platforms remains to be seen. But with multiple data readouts expected in 2026 and regulatory decisions pending in both the U.S. and Japan, the coming year should provide meaningful clarity on Alpha DaRT’s potential.

Big Pharma Has Spent $8 Billion on Targeted Radiation. Alpha Tau Is Building for the Tumors They Can’t Reach

Subscribe for Similar Reports

Read More from The Finance Herald